European Journal of Nutrition

, Volume 50, Issue 8, pp 673–680 | Cite as

Lack of effect of oral administration of resveratrol in LPS-induced systemic inflammation

  • M. Larrosa
  • M. Azorín-Ortuño
  • M. J. Yañez-Gascón
  • M. T. García-Conesa
  • F. Tomás-Barberán
  • J. C. Espín
Original Contribution

Abstract

Purpose

The high mortality index due to sepsis and the lack of an effective treatment requires the search for new compounds that can serve as therapy for this disease. Resveratrol, a well-known anti-inflammatory natural compound, might be a good candidate for the treatment of sepsis. The aim of this work was to study the effects of oral administration of resveratrol, before and after sepsis initiation, on inflammation markers in a murine model of endotoxin-induced sepsis.

Methods

Sprague–Dawley male rats were treated with resveratrol the 3 days prior to LPS administration and 45 min later. Hematological parameters, TNF-α, IL-1β and CINC-1, FRAP and TBARS levels were determined. Resveratrol and resveratrol-derived metabolites profile in plasma was compared after oral and intraperitoneal administration.

Results

Oral treatment with resveratrol had no apparent systemic protective effects. However, resveratrol reduced the levels of lipid peroxidation in the small intestine and colon. Importantly, the administration of LPS caused a decrease in resveratrol absorption. When resveratrol bioavailability after i.p. administration was compared to that observed after oral administration, a different profile of resveratrol metabolites was found in plasma.

Conclusion

These results highlight the importance of studying the bioavailability of the assayed compounds in the experimental models used to be able to choose the best route of administration depending on the target organ and to determine which compounds or derived metabolites are effective treating the studied disease.

Keywords

Polyphenol Lipopolysaccharide endotoxin Sepsis Cytokines Bioavailability 

References

  1. 1.
    Annane D, Bellissant E, Cavaillon JM (2005) Septic shock. Lancet 365:63–78CrossRefGoogle Scholar
  2. 2.
    Martin GS, Mannino DM, Eaton S, Moss M (2000) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348:1546–1554CrossRefGoogle Scholar
  3. 3.
    Winters BD, Eberlein M, Leung J, Needham DM, Pronovost PJ, Sevransky JE (2010) Long-term mortality and quality of life in sepsis: a systematic review. Crit Care Med 38:1276–1283Google Scholar
  4. 4.
    Baur JA, Sinclair DA (2006) Therapeutic potential or resveratrol: the in vivo evidence. Nat Rev 5:493–506CrossRefGoogle Scholar
  5. 5.
    Ma ZH, Ma QY, Wang LC, Sha HC, Wu SL, Zhang M (2005) Effect of resveratrol on peritoneal macrophages in rats with severe acute pancreatitis. Inflamm Res 54:522–527CrossRefGoogle Scholar
  6. 6.
    Elmali N, Baysal O, Harma A, Esenkaya I, Mizrak B (2007) Effects of resveratrol in inflammatory arthritis. Inflammation 30:1–6CrossRefGoogle Scholar
  7. 7.
    Larrosa M, Yañéz-Gascón MJ, Selma MV, González-Sarrías A, Toti S, Cerón JJ, Tomás-Barberán F, Dolara P, Espín JC (2009) Effect of a low dose of dietary resveratrol on colon microbiota, inflammation and tissue damage in a DSS-induced colitis rat model. J Agric Food Chem 57:2211–2220CrossRefGoogle Scholar
  8. 8.
    Sebai H, Gadacha W, Sani M, Aouani E, Ghanem-Boughanmi N, Ben-Attia M (2009) Protective effect of resveratrol against lipopolysaccharide-induced oxidative stress in rat brain. Brain Inj 23:1089–1094CrossRefGoogle Scholar
  9. 9.
    Sebai H, Sani M, Yacoubi MT, Aouani E, Ghanem-Boughanmi N, Ben-Attia M (2010) Resveratrol, a red wine polyphenol, attenuates lipopolysaccharide-induced oxidative stress in rat liver. Ecotoxicol Environ Saf 73:1078–1083CrossRefGoogle Scholar
  10. 10.
    Sebai H, Ben-Attia M, Sani M, Aouani E, Ghanem-Boughanmi N (2008) Protective effect of resveratrol on acute endotoxemia-induced nephrotoxicity in rat through nitric oxide independent mechanism. Free Radic Res 42:913–920CrossRefGoogle Scholar
  11. 11.
    Sebai H, Sani M, Ghanem-Boughanmi N, Aouani E (2010) Prevention of lipopolysaccharide-induced mouse lethality by resveratrol. Food Chem Toxicol 48:1543–1549CrossRefGoogle Scholar
  12. 12.
    Requintina PJ, Oxenkrug GF (2003) Differential effects of lipopolysaccharide on lipid peroxidation in F344 N, SHR rats and BALB/c mice, and protection of melatonin and NAS against its toxicity. Ann NY Acad Sci 993:325–333CrossRefGoogle Scholar
  13. 13.
    Suliburk JW, Ward JL, Helmer KS, Adams SD, Zuckerbraun BS, Mercer DW (2009) Ketamine-induced hepatoprotection: the role of heme oxygenase-1. Am J Physiol Gastrointest Liver Physiol 296:1360–1369CrossRefGoogle Scholar
  14. 14.
    Kubota S, Kurihara T, Mochimaru H, Satofuka S, Noda K, Ozawa Y, Oike Y, Ishida S, Tsubota K (2009) Prevention of ocular inflammation in endotoxin-induced uveitis with resveratrol by inhibiting oxidative damage and nuclear factor-kappaB activation. Invest Ophthalmol Vis Sci 50:3512–3519CrossRefGoogle Scholar
  15. 15.
    Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited. Faseb J 22:659–661CrossRefGoogle Scholar
  16. 16.
    Larrosa M, González-Sarrías A, Yáñez-Gascón MJ, Selma MV, Azorín-Ortuño M, Toti S, Tomás-Barberán F, Dolara P, Espín JC (2010) Anti-inflammatory properties of a pomegranate extract and its metabolite urolithin-A in a colitis rat model and the effect of colon inflammation on phenolic metabolism. J Nutr Biochem 21:717–725CrossRefGoogle Scholar
  17. 17.
    Pyles LA, Stejskal EJ, Einzig S (1993) Spectrophotometric measurement of plasma 2-thiobarbituric acid-reactive substances in the presence of hemoglobin and bilirubin interference. Proc Soc Exp Biol Med 202:407–419Google Scholar
  18. 18.
    Azorín-Ortuño M, Yañez-Gascón MJ, Pallarés F, Vallejo F, Larrosa M, García-Conesa MT, Tomas-Barberán F, Espín JC (2010) Pharmacokinetic study of trans-resveratrol in adult pigs. J Agric Food Chem 58:11165–11171CrossRefGoogle Scholar
  19. 19.
    Larrosa M, Tomé-Carneiro J, Yáñez-Gascón MJ, Alcántara D, Selma MV, Beltrán D, García-Conesa MT, Urbán C, Lucas R, Tomás-Barberán F, Morales JC, Espín JC (2010) J Med Chem 53:7365–7376CrossRefGoogle Scholar
  20. 20.
    Toussaint S, Gerlach H (2009) Activated protein C for sepsis. N Engl J Med Dec 361:2646–2652CrossRefGoogle Scholar
  21. 21.
    Poli-de-Figueiredo LF, Garrido AG, Nakagawa N, Sannomiya P (2008) Experimental models of sepsis and their clinical relevance. Shock 30:53–59CrossRefGoogle Scholar
  22. 22.
    Lu CC, Lai HC, Hsieh SC, Chen JK (2008) Resveratrol ameliorates Serratia marcescens-induced acute pneumonia in rats. J Leukoc Biol 83:1028–1037CrossRefGoogle Scholar
  23. 23.
    Jung HJ, Hwang IA, Sung WS, Kang H, Kang BS, Seu YB, Lee DG (2005) Fungicidal effect of resveratrol on human infectious fungi. Arch Pharm Res 28:557–560CrossRefGoogle Scholar
  24. 24.
    Campagna M, Rivas C (2010) Antiviral activity of resveratrol. Biochem Soc Trans 38:50–53CrossRefGoogle Scholar
  25. 25.
    Ayala A, Herdon CD, Lehman DL, Ayala CA, Chaudry IH (1996) Differential induction of apoptosis in lymphoid tissues during sepsis: variation in onset, frequency, and the nature of the mediators. Blood 87:4261–4275Google Scholar
  26. 26.
    Hotchkiss RS, Tinsley KW, Swanson PE, Chang KC, Cobb JP, Buchman TG, Korsmeyer SJ, Karl IE (1999) Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc Natl Acad Sci USA 96:14541–14546CrossRefGoogle Scholar
  27. 27.
    Zunino SJ, Storms DH (2009) Resveratrol alters proliferative responses and apoptosis in human activated B lymphocytes in vitro. J Nutr 139:1603–1608CrossRefGoogle Scholar
  28. 28.
    Sebai H, Ben-Attia M, Sani M, Aouani E, Ghanem-Boughanmi N (2009) Protective effect of resveratrol in endotoxemia-induced acute phase response in rats. Arch Toxicol 83:335–340CrossRefGoogle Scholar
  29. 29.
    Birrell MA, McCluskie K, Wong S, Donnelly LE, Barnes PJ, Belvisi MG (2005) Resveratrol, an extract of red wine, inhibits lipopolysaccharide induced airway neutrophilia and inflammatory mediators through an NF-kappaB-independent mechanism. FASEB J 19:840–851Google Scholar
  30. 30.
    Wenzel E, Soldo T, Erbersdobler H, Somoza V (2005) Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. Mol Nutr Food Res 49:482–494CrossRefGoogle Scholar
  31. 31.
    Breedveld P, Pluim D, Cipriani G, Dahlhaus F, van Eijndhoven MA, de Wolf CJ, Kuil A, Beijnen JH, Scheffer GL, Jansen G, Borst P, Schellens JH (2007) The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol 71:240–249CrossRefGoogle Scholar
  32. 32.
    van de Wetering K, Burkon A, Feddema W, Bot A, de Jonge H, Somoza V, Borst P (2009) Intestinal breast cancer resistance protein (BCRP)/Bcrp1 and multidrug resistance protein 3 (MRP3)/Mrp3 are involved in the pharmacokinetics of resveratrol. Mol Pharmacol 75:876–885CrossRefGoogle Scholar
  33. 33.
    Alfaras I, Pérez M, Juan ME, Merino G, Prieto JG, Planas JM, Alvarez AL (2010) Involvement of breast cancer resistance protein (BCRP1/ABCG2) in the bioavailability and tissue distribution of trans-resveratrol in knockout mice. J Agric Food Chem 58:4523–4528CrossRefGoogle Scholar
  34. 34.
    Juan ME, González-Pons E, Planas JM (2010) Multidrug resistance proteins restrain the intestinal absorption of trans-resveratrol in rats. J Nutr 140:489–495CrossRefGoogle Scholar
  35. 35.
    Kalitsky-Szirtes J, Shayeganpour A, Brocks DR, Piquette-Miller M (2004) Suppression of drug-metabolizing enzymes and efflux transporters in the intestine of endotoxin-treated rats. Drug Metab Dispos 32:20–27CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • M. Larrosa
    • 1
  • M. Azorín-Ortuño
    • 1
  • M. J. Yañez-Gascón
    • 1
  • M. T. García-Conesa
    • 1
  • F. Tomás-Barberán
    • 1
  • J. C. Espín
    • 1
  1. 1.Department of Food Science and TechnologyResearch Group on Quality, Safety and Bioactivity of Plant Foods, CEBAS-CSICMurciaSpain

Personalised recommendations